NCT05184712 2026-03-04
Phase 3 Clinical Study of AK112 for NSCLC Patients
Akeso
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT06956001 2026-02-12
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06970639 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT04996017 2025-03-13
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Recruiting
NCT06612151 2025-02-11
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT04241315 2023-03-23
Elucidate
On Target Laboratories, LLC
Phase 3 Completed
NCT04840290 2021-04-21
A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC
Tang-Du Hospital
Phase 3 Unknown
NCT02667743 2021-03-17
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04203485 2020-05-08
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03083743 2017-03-20
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection
Shanghai Gebaide Biotechnology Co., Ltd.
Phase 3 Unknown
NCT00080340 2008-01-15
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Telik
Phase 3 Completed